Zim Laboratories Ltd (ZIMLAB) is currently trading at 134.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zim Laboratories Limited is an Indian formulations manufacturer focused on branded generics, nutraceuticals and innovative delivery platforms—including the Thinoral oral thin film (OTF) technology—and exports a majority of its production to RoW and regulated markets while operating subsidiaries to support international filings and commercialization. Q3FY26 showed a meaningful operational recovery: Total operating income rose to ₹1,087 million (+12.8% YoY) with EBITDA of ₹145 million and positive PAT of ₹44 million, reflecting sequential margin recovery driven by higher export volumes and a strong uptick in the Nutra business, which grew 93% QoQ in Q3FY26. Zim Laboratories is heavily export‑oriented (88% of Q3FY26 revenue) and is actively commercializing NIP and OTF pipelines for EU/UK markets, with seven NIP filings reported and several products in BE, regulatory filing and commercial supply stages, indicating a strategic pivot toward higher‑value regulated markets. Management has approved a preferential allotment to raise up to ₹35 crore from Florintree Trinex LLP to fund a dedicated facility for Star Product 2, a standalone nutraceutical facility and CAPA remediation; the company is also progressing CAPA remediation to be inspection‑ready from March 2026 onwards, which is material for regulatory clearance and future launches. R&D intensity is high by domestic peer standards with ₹230 million invested in 9MFY26 (8.6% of operating income), a 96‑strong R&D team and four technology platforms, signalling that Zim Laboratories is investing to move up the value chain via innovative formulations and dossier‑driven regulated market entries.

Over the past 52 weeks, Zim Laboratories Ltd has traded between a low of ₹59.72 and a high of ₹136.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zim Laboratories Ltd has a market capitalization of approximately 693.00. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zim Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 187.30 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 693.00 Cr, Zim Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zim Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zim Laboratories Ltd is 187.30. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board meeting is scheduled for Tuesday, May 19, 2026.